Cellectar Biosciences, Inc. (CLRB) insider buying and selling
There were no open-market insider purchases or sales at Cellectar Biosciences, Inc. (CLRB) in the last 90 days. Over the last 12 months, 2 insiders bought $50K of the stock, led by JAMES CARUSO V (CEO), who bought $25K on May 7, 2026.
This is the public summary. Create a free account to see CLRB’s AI Signal, the price chart with every insider trade plotted, and each insider’s track record.
Unlock CLRBRecent open-market insider trades
Trades by the same insider within a week are shown as one line.
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| JAMES CARUSO V CEO | Open market purchase | 8,680 | $2.88 | $25K | |
| Jarrod Longcor COO | Open market purchase | 8,680 | $2.88 | $25K |
What the CLRB insider trades really mean
The table above is the public summary. With an Insider Intel account you get the analysis behind it, for Cellectar Biosciences, Inc. and every other stock we track:
CLRB's AI Signal score
One score from six weighted factors, with the full breakdown behind it, so you can see whether the buying is a real signal.
Unlock with a free accountEvery trade on the price chart
See each CLRB insider purchase and sale plotted on the chart, with the gain or loss on every one since.
Unlock with a free accountInsider track records
Is JAMES CARUSO V worth following? See their grade, win rate and average return on past purchases.
Unlock with a free accountAnalysts vs insiders
The consensus rating and price target next to the insider activity. Do the analysts agree?
Unlock with a free accountTrading windows
See when CLRB insiders are likely free to trade, shaded on the chart, so you know when to expect new filings.
Unlock with a free accountAlerts the moment they file
Get an email, Slack or in-app alert when a CLRB insider files, plus alerts for cluster buying.
Unlock with a free accountPlus AI summaries, the latest news for each stock, and an AI assistant you can ask questions about any of it.
Questions about CLRB insider trading
Who bought Cellectar Biosciences, Inc. (CLRB) stock recently?
Insiders who bought Cellectar Biosciences, Inc. stock on the open market in the last 12 months: JAMES CARUSO V ($25K), Jarrod Longcor ($25K). The most recent purchase was reported on May 7, 2026.
Are insiders buying or selling CLRB?
Over the last 12 months insiders were net buyers of CLRB on discretionary trades: $50K bought against $0 sold (scheduled and tax-related sales excluded).
What is a sell-to-cover or 10b5-1 sale?
A 10b5-1 sale is scheduled in advance under a pre-arranged plan, and a sell-to-cover sale is made to pay tax on vesting shares. Neither is a fresh decision to sell, so they say less about an insider's view than a discretionary sale.
Where does this data come from?
Officers, directors and large shareholders report their trades to the SEC on Form 4. This page lists the open-market purchases and sales by individual insiders from those public filings; funds and other institutions are not shown.
Other stocks with recent insider buying
- MAIR · Madison Air Solutions Corp$219.6M bought by insiders, last 90 days
- BRVE · Braveheart Bio, Inc.$39.5M bought by insiders, last 90 days
- PAMT · PAMT CORP$31.2M bought by insiders, last 90 days
- AUGO · Aura Minerals Inc.$22.7M bought by insiders, last 90 days
- ET · Energy Transfer$21.5M bought by insiders, last 90 days
- AAT · American Assets Trust, Inc.$18.2M bought by insiders, last 90 days
Create a free account and open its chart, score and alerts.
How to read this page
Officers, directors and large shareholders must report their trades in company shares to the SEC on Form 4. This page lists open-market purchases and sales by individual insiders: trades made on the stock exchange at the going price. Funds and other institutions are not shown here.
Information from SEC EDGAR Form 4 filings, shown for general information only. It is not financial advice and does not recommend buying or selling any security. Trades are shown by transaction date and may be reported up to two business days later.